In the NF1-glioma cohort, median overall survival for patients with an ALT-positive tumor was only 18 months and significantly differed compared to patients with either long (69 months) or normal telomeres (not reached) (p < 0.0001, log rank test). The gene discussed is NF1; the disease is central nervous system cancer.